Jill Hallin
PhD
Vice President, Translational Sciences
👥Biography 个人简介
Jill Hallin led the preclinical characterization of adagrasib (MRTX849) that established its pharmacologic properties favoring CNS penetration and combination potential. Her translational science work defined rational combinations with SHP2 and CDK inhibitors. She has contributed to understanding KRAS G12C inhibitor activity in brain metastases.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Jill Hallin 的研究动态
Follow Jill Hallin's research updates
留下邮箱，当我们发布与 Jill Hallin（Mirati Therapeutics）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment